{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:49:56Z","timestamp":1791560996695,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02988-w","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:49:19Z","timestamp":1784551759000},"page":"1368-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-2328","authenticated-orcid":false,"given":"Enrico","family":"Maffini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7774","authenticated-orcid":false,"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"It\u00e4la-Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Luc\u00eda L\u00f3pez","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Pavlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2988_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transpl. 2025;60:519\u201328.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41409-024-02459-0","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, et al. Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. Bone Marrow Transpl. 2025;60:227\u201336.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.94952","volume":"6","author":"J Sawyer","year":"2024","unstructured":"Sawyer J, Elliott T, Orton L, Sowell H, Gatwood K, Shultes K, et al. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int. 2024;6:1\u201310.","journal-title":"Clin Hematol Int"},{"key":"2988_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46989\/001c.124926","volume":"6","author":"R Shah","year":"2024","unstructured":"Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al. Multidisciplinary management of morbidities associated with chronic graft-versus-host disease. Clin Hematol Int. 2024;6:74\u201388.","journal-title":"Clin Hematol Int"},{"key":"2988_CR5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","volume":"8","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332\u201341.","journal-title":"Blood Adv"},{"key":"2988_CR6","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","volume":"33","author":"YL Kasamon","year":"2015","unstructured":"Kasamon YL, Bolanos-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152\u201361.","journal-title":"J Clin Oncol"},{"key":"2988_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR8","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood.V93.7.2196","volume":"93","author":"O Ringd\u00e9n","year":"1999","unstructured":"Ringd\u00e9n O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood. 1999;93:2196\u2013220.","journal-title":"Blood"},{"key":"2988_CR9","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","volume":"84","author":"RA Clift","year":"1994","unstructured":"Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036\u201343.","journal-title":"Blood"},{"key":"2988_CR10","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood.V94.11.3960a","volume":"94","author":"RA Clift","year":"1999","unstructured":"Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood. 1999;94:3960\u20132.","journal-title":"Blood"},{"key":"2988_CR11","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen\u2014a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2013;31:3549\u201356.","journal-title":"J Clin Oncol"},{"key":"2988_CR12","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson C, LeRademacher J, Kato K, DiPersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122:3871\u20138.","journal-title":"Blood"},{"key":"2988_CR13","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","volume":"122","author":"EA Copelan","year":"2013","unstructured":"Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863\u201370.","journal-title":"Blood"},{"key":"2988_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia. Bone Marrow Transpl. 2020;55:1114\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","volume":"59","author":"A Spyridonidis","year":"2024","unstructured":"Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024;59:217\u201323.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"2988_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Nagler A, Savani BN. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clin Hematol Int. 2020;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2988_CR18","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Betty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Soci\u00e9 G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transpl. 2005;11:945\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GVHD-free, relapse-free survival for registry-based studies: an ALWP\u2013EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610\u20131.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hon.3160","volume":"41","author":"C Nunez-Torr\u00f2n Stock","year":"2023","unstructured":"Nunez-Torr\u00f2n Stock C, Jimenez Chill\u00f2n C, Martin Moro F, Marquet Palomanes J, Velazquez Kennedy K, Piris Villaespesas M, et al. Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry. Hematol Oncol. 2023;41:753\u201361.","journal-title":"Hematol Oncol"},{"key":"2988_CR22","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.23375","volume":"112","author":"M Sorror","year":"2008","unstructured":"Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992\u20132001.","journal-title":"Cancer"},{"key":"2988_CR23","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","volume":"98","author":"L Luznik","year":"2001","unstructured":"Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456\u201364.","journal-title":"Blood"},{"key":"2988_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.bbmt.2018.09.042","volume":"25","author":"GL Chen","year":"2019","unstructured":"Chen GL, Hahn T, Wilding GE, Groman A, Hutson A, Zhang Y, et al. Reduced-intensity conditioning with fludarabine, melphalan, and total body irradiation for allogeneic hematopoietic cell transplantation: the effect of increasing melphalan dose on underlying disease and toxicity. Biol Blood Marrow Transpl. 2019;25:689\u201398.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12185-021-03233-4","volume":"115","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, et al. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine\/low-dose melphalan plus 4 Gy TBI versus fludarabine\/ busulfan plus 4 Gy TBI. Int J Hematol. 2022;115:244\u201354.","journal-title":"Int J Hematol"},{"key":"2988_CR26","first-page":"492.e1","volume":"27","author":"B Sarina","year":"2021","unstructured":"Sarina B, Mancosu P, Navarria P, Bramanti S, Mariotti J, De Philippis C, et al. Nonmyeloablative conditioning regimen including low-dose total marrow\/lymphoid irradiation before haploidentical transplantation with post-transplantation cyclophosphamide in patients with advanced lymphoproliferative diseases. Transpl Cell Ther. 2021;27:492.e1\u2013e6.","journal-title":"Transpl Cell Ther"},{"key":"2988_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"1","author":"AM Raiola","year":"2013","unstructured":"Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transpl. 2013;1:117\u2013122.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR28","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/ajh.25934","volume":"95","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Labopin M, Angelucci E, Ciceri F, Diez-Martin JL, Bruno B, et al. Impact of total body irradiation vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. Am J Hematol. 2020;95:1200\u20138.","journal-title":"Am J Hematol"},{"key":"2988_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106969","volume":"123","author":"N Shah","year":"2022","unstructured":"Shah N, Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, et al. Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity\/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide. Leuk Res. 2022;123:106969.","journal-title":"Leuk Res"},{"key":"2988_CR30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41409-022-01674-x","volume":"57","author":"R Devillier","year":"2022","unstructured":"Devillier R, Galimard JE, Labopin M, Blaise D, Raiola AM, Pavlu J, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transpl. 2022;57:1421\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR31","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.bbmt.2019.06.017","volume":"25","author":"SR Solomon","year":"2019","unstructured":"Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A. Fludarabine and total-body irradiation conditioning before ablative haploidentical transplantation: long-term safety and efficacy. Biol Blood Marrow Transpl. 2019;25:2211\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3324\/haematol.2018.199398","volume":"104","author":"F Monaco","year":"2019","unstructured":"Monaco F, Scott BL, Chauncey TR, Petersen FB, Storer BE, Baron F, et al. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica. 2019;104:1221\u20139.","journal-title":"Haematologica"},{"key":"2988_CR33","first-page":"1003.e1","volume":"27","author":"RS Mehta","year":"2021","unstructured":"Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, et al. Bone marrow versus peripheral blood grafts for haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transpl Cell Ther. 2021;27:1003.e1\u20131003.e13.","journal-title":"Transpl Cell Ther"},{"key":"2988_CR34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","volume":"13","author":"M Bornhauser","year":"2012","unstructured":"Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035\u201344.","journal-title":"Lancet Oncol"},{"key":"2988_CR35","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","volume":"5","author":"F Fasslrinner","year":"2018","unstructured":"Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5:e161\u2013e169.","journal-title":"Lancet Haematol"},{"key":"2988_CR36","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/j.bbmt.2019.08.005","volume":"25","author":"R Storb","year":"2019","unstructured":"Storb R, Georges GE, Gooley TA. Total body irradiation\u2013based versus chemotherapy-based myeloablative conditioning for allogeneic hematopoietic cell transplant. Biol Blood Marrow Transpl. 2019;25:e356\u201362.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR37","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1182\/blood.V83.11.3384.3384","volume":"83","author":"R Storb","year":"1994","unstructured":"Storb R, Raff RF, Appelbaum FR, Deeg HJ, Graham TC, Schuening FG, et al. Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. Blood. 1994;83:3384\u20139.","journal-title":"Blood"},{"key":"2988_CR38","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41409-020-01074-z","volume":"56","author":"A Bazarbachi","year":"2021","unstructured":"Bazarbachi A, Labopin M, Blaise D, Forcade E, Soci\u00e9 G, Berceanu A, et al. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine\/busulfan conditioning for acute myeloid leukemia. Bone Marrow Transpl. 2021;56:622\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"2988_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","volume":"26","author":"F Sor\u00e0","year":"2020","unstructured":"Sor\u00e0 F, Di Grazia C, Chiusolo P, Raiola AM, Bregante S, Mordini N, et al. Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (buflu) or thiotepa, busulfan, and fludarabine (TBF): a Retrospective study. Biol Blood Marrow Transpl. 2020;26:698\u2013703.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR40","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/bloodadvances.2023011759","volume":"8","author":"AM Raiola","year":"2024","unstructured":"Raiola AM, Di Grazia C, Dominietto A, Bregante S, Giammarco S, Varaldo R, et al. Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up. Blood Adv. 2024;8:1964\u20137.","journal-title":"Blood Adv"},{"key":"2988_CR41","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","volume":"25","author":"T Pagliardini","year":"2019","unstructured":"Pagliardini T, Castagna L, Harbi S, Della Porta M, Rey J, Furst S, et al. Thiotepa, fludarabine, and busulfan conditioning regimen before T-cell replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients. Biol Blood Marrow Transpl. 2019;25:1803\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR42","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/cncr.26539","volume":"118","author":"M Fang","year":"2012","unstructured":"Fang M, Storer B, Wood B, Gyurkocza B, Sandmaier BM, Appelbaum FR. Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation: cytogenetics-flow comparison in AML. Cancer. 2012;118:2411\u20139.","journal-title":"Cancer"},{"key":"2988_CR43","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3324\/haematol.2022.281585","volume":"108","author":"C Orvain","year":"2023","unstructured":"Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodriguez-Arboli E, Wood BL, et al. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Haematologica. 2023;108:420\u201332.","journal-title":"Haematologica"},{"key":"2988_CR44","first-page":"P773.E1","volume":"28","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Dholaria B, Ciceri F, Fraccaroli A, Blaise D, et al. Impact of cytogenetic risk on outcomes of non\u2013T\u2013cell\u2013depleted haploidentical hematopoietic cell transplantation in patients with relapsed or refractory acute myeloid leukemia. Biol Blood Marrow Transpl. 2022;28:P773.E1\u2013773.E8.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2988_CR45","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/cncr.28768","volume":"120","author":"S Giebel","year":"2014","unstructured":"Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:2760\u20135.","journal-title":"Cancer"},{"key":"2988_CR46","doi-asserted-by":"publisher","unstructured":"Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica 2020;105:https:\/\/doi.org\/10.3324\/haematol.2019.245688.","DOI":"10.3324\/haematol.2019.245688"},{"key":"2988_CR47","first-page":"620.e1","volume":"27","author":"F Khimani","year":"2021","unstructured":"Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, et al. Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis. Transpl Cell Ther. 2021;27:620.e1\u2013620.e9.","journal-title":"Transpl Cell Ther"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02988-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02988-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02988-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:02:01Z","timestamp":1791558121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02988-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2988"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02988-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed according to the relevant guidelines and regulations. Informed consent was obtained from all patients. The scientific boards of the ALWP of the EBMT approved this study.","order":2,"name":"Ethics","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPAT","group":{"name":"EthicsHeading","label":"Ethics"}}]}}